Fig. 2
From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Estimated lethality rates at 14 and 30Â days by baseline characteristics of patients in the phase 2 ITT population. Red dash lines represent lethality rates under null hypotheses